STONE CIRCLE OF FRIENDS – Cure Myotonic Muscular Dystrophy

Home About us WHAT IS MMD?RESEARCH WAYS TO HELP CALENDAR EVENTS NEWS Newsletter CONTACT US

Welcome to the Stone Circle of Friends

The Stone Circle of Friends is a non-profit organization committed to expediting a therapy or a cure for Myotonic Muscular Dystrophy. Our focus is to raise funds to directly support promising research conducted at the University of Virginia by Dr. Mani Mahadevan and his lab. Myotonic Muscular Dystrophy (MMD) is the number one inherited neuromuscular disease in the United States and it kills one quarter of the most affected newborns. Those who survive face a lifetime of challenges. At this time there is no treatment or cure.

Please consider giving generously to help the research outpace the progression of this illness in the current generation.

Todd Stone, cofounder of the Stone Circle of Friends, has produced these compelling videos describing the mission he and his family have undertaken - to fight Myotonic Muscular Dystrophy by helping to fund vital research. According to researchers, the cure is within reach but funding is a major obstacle. The Stones are seeking to give their two boys and others with MMD a chance to thrive in a healthy body, with clear minds and a strong heart. Please consider how you can give to help expedite a cure and make a change in the world.

Quicktime Player Required
Click Here to Download

Iplex Study

If you are an adult with MMD, please consider participating in this clinical study to test a promising medication called Iplex. It has been tolerated well and is helping with various symptoms of MMD. They need 60 subjects to start the phase II of this study.

Insmed Incorporated of Richmond, Virginia is developing rhIGF-I/rhIGFBP-3 for the treatment of symptoms associated with myotonic muscular dystrophy (DM1). In a preliminary, open-label study in adults with DM1, the medication was well tolerated and was associated with improvements in muscle mass, lipids, gastrointestinal function, endurance and cognitive function. Insmed is currently enrolling adult DM1 patients in a 6-month, double-blind, placebo-controlled study with rhIGF-I/rhIGFBP-3. This study is being conducted at several locations around the United States and is supported by a grant from the Muscular Dystrophy Association. For more information, go to www.mda.org or www.insmed.com or contact Insmed at (804) 565-3130 or clinicaltrials@insmed.com.